Bingnan Gu
Senior Director - Viral Vector, Cell Therapy, R&D Lonza
Bingnan has over twenty years research and development experience in academia and industry, focused on stem cell regulation, cell line and vector engineering, and cell and gene therapy (CGT) manufacturing process and analytics innovation. He leads the group of R&D scientists for the development of Lonza’s proprietary AAV, lentivirus, and cell therapy manufacturing platforms. Bingnan earned his PhD degree in molecular medicine from the University of Texas Health Science Center at San Antonio, MBA from the University of Texas at Austin, and Bachelor in life sciences from Fudan University in China.
Seminars
Wednesday 25th February 2026
Advancing Lentiviral Vector Yield, Quality & Commercial Readiness from Transient Transfection Platform to Stable Producer Cell Lines
11:00 am
- A robust lentiviral transient transfection platform delivering high, consistent yields at scale
- Deep analytical profiling of LVV genome integrity and packaging efficiency to drive reliable, high‑quality vector production
- Next‑gen LVV producer cell lines to enable high-volume supply with improved quality and lower COGS
